Trial Profile
A Phase II Proof of Principle Study of the Activity of Pembrolizumab (MK-3475) in Combination With SBRT in Primary Tyrosine Kinase Inhibitor (TKI) Refractory Metastatic Kidney Cancer (mRCC) Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Renal cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms OZM-065
- 26 Aug 2021 Status changed from recruiting to completed.
- 18 Mar 2021 Planned End Date changed from 1 Mar 2021 to 1 Dec 2021.
- 18 Mar 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.